Mankind Pharma Q4 FY25: Revenue up 27%, PAT slips

Key takeaway from Q4 FY25

Mankind Pharma reported strong top-line growth in the March 2025 quarter (Q4 FY25), supported by chronic therapies, consumer healthcare momentum and consolidation of Bharat Serums and Vaccines (BSV). However, net profit declined year-on-year as the company absorbed integration costs and faced regulatory challenges in its acute therapy portfolio. The company also highlighted a sharper jump in exports during the quarter, with management describing the international performance as aided by specific opportunities.

Headline financial performance for the quarter

For Q4 FY25, Mankind Pharma’s revenue was reported at ₹3,079.4 crore, up 27.1% year-on-year. Adjusted EBITDA margin was cited at 23.1% in the company commentary, while another report put the reported EBITDA margin at 22.2% versus 24.2% a year earlier.

Net profit figures for the quarter differed across sources in the provided material. One report mentioned profit of ₹420.8 crore (down 10.7% YoY), while another summary cited PAT of ₹429 crore (down 10%). The common message across both was that profit fell despite faster revenue growth.

What drove growth: domestic business and chronic therapies

Domestic revenue in Q4 FY25 rose 18% year-on-year. A key driver was chronic therapies, where the company indicated strong outperformance versus the Indian Pharmaceutical Market (IPM). It also pointed to the consolidation of the BSV business as an incremental support to growth.

Management commentary highlighted that, excluding BSV, chronic share increased to 39.2% in Q4 FY25 from 37.5% in the year-ago quarter. The company also reported chronic therapy growth of 11%, compared with 8.7% growth in IPM chronic.

In specific chronic segments, the company stated outperformance against IPM, including 1.5x in cardiac and 1.3x in anti-diabetics. It also said it retained the top rank in prescriptions for the eighth consecutive year.

Consumer healthcare: steady build, faster growth in channels

Mankind said FY25 marked a shift in its consumer healthcare business as prior strategic initiatives began to show benefits from the second quarter onward. In Q4 FY25, consumer healthcare revenue stood at ₹178 crore, up 14% year-on-year.

For the full year, consumer healthcare revenue was reported at ₹809 crore, up 15%. The company also highlighted strong channel traction, reporting 77% year-on-year growth in modern trade and e-commerce channels.

Exports: sharp jump in Q4, strong FY25 growth

International business was a major swing factor in the quarter. Exports in Q4 FY25 doubled to ₹535 crore from ₹267 crore in Q4 FY24, as per the company commentary. Another report described the export performance as supported by “one-off opportunities in the United States.”

For FY25, international revenue rose 88% to ₹1,532 crore. The company also disclosed organic growth of 37% for international markets in FY25, alongside the reported jump in revenues.

BSV integration and specialty portfolio updates

Mankind acquired BSV to strengthen its presence in gynaecology and super-specialty therapies, and management said integration progress continued through Q4. Vice Chairman and Managing Director Rajeev Juneja cited BSV synergies of ₹50 to ₹100 crore over 12 to 24 months.

Operationally, the company flagged traction in amphotericin, noting that a recent launch gained more than 8% volume market share in March 2025 and ranked among the top three launches. It also provided an R&D update, stating that GPR-119 advanced to Phase II.

FY25 numbers: revenue milestone and margin profile

For FY25, Mankind Pharma reported revenue of ₹12,207 crore, up 19% year-on-year. Domestic sales contributed ₹10,675 crore, crossing the ₹10,000 crore milestone and rising 13% year-on-year.

Adjusted EBITDA margin for FY25 was reported at 25.9%, with adjusted EBITDA at ₹3,159 crore. Separately, a highlight note referenced FY25 net debt of ₹5,784 crore and a net debt-to-EBITDA ratio of 1.8x.

Margin pressure and what the company attributed it to

Even as EBITDA grew year-on-year in Q4 FY25, margin pressure was flagged. The provided report attributed the decline in EBITDA margin to integration costs linked to BSV and continuing regulatory challenges in the acute therapy segment.

This context is important because Mankind has historically been seen as a strong domestic formulations player. In the quarter, the company continued to position chronic and consumer healthcare as key legs of growth, while acknowledging near-term pressures in acute.

Market view and management’s FY26 targets

The provided material included a market view calling Mankind Pharma (MANKIND.NS) a “BUY,” citing strong revenue growth, BSV integration, consumer healthcare traction and “robust cash flows” of ₹2,413 crore, alongside debt reduction.

On guidance-style targets, management said it aims to deliver 1.2x IPM domestic growth and an EBITDA margin of 25% to 26% in FY25/26.

Snapshot table: key disclosed metrics (all ₹ in crore)

Why the quarter matters for investors

The quarter combined two contrasting signals: faster revenue growth and weaker year-on-year profit. The top line was supported by a higher chronic contribution, stronger exports and BSV consolidation, while margin and profit were affected by integration costs and acute regulatory headwinds.

The next set of disclosures around BSV synergy realization, the durability of export gains (especially if they were opportunity-led), and consumer healthcare scaling will likely remain key items investors track against the company’s FY26 margin and growth targets.

Conclusion

Mankind Pharma ended FY25 with revenue of ₹12,207 crore and domestic revenue of ₹10,675 crore, while Q4 FY25 showed sharp growth in exports and steady expansion in chronic and consumer healthcare. The company has outlined FY26 goals of 1.2x IPM domestic growth and 25% to 26% EBITDA margin, alongside stated BSV synergy targets over 12 to 24 months.